1. Home
  2. AMPY vs MDXH Comparison

AMPY vs MDXH Comparison

Compare AMPY & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amplify Energy Corp.

AMPY

Amplify Energy Corp.

HOLD

Current Price

$5.17

Market Cap

190.6M

Sector

Energy

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.51

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPY
MDXH
Founded
2011
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
190.6M
183.4M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
AMPY
MDXH
Price
$5.17
$3.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
570.0K
123.5K
Earning Date
03-04-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$275,827,100.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$2.27
$1.35
52 Week High
$6.55
$5.33

Technical Indicators

Market Signals
Indicator
AMPY
MDXH
Relative Strength Index (RSI) 54.04 48.33
Support Level $5.18 $3.45
Resistance Level $5.75 $3.80
Average True Range (ATR) 0.26 0.20
MACD 0.04 -0.02
Stochastic Oscillator 47.12 27.50

Price Performance

Historical Comparison
AMPY
MDXH

About AMPY Amplify Energy Corp.

Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: